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The multiple biological activities present in semipurified lymphokine prepa- 
rations  have  made  it  difficult to  assign  discrete biological  functions  to  each 
lymphokine. As a  result, the large number of identified lymphokine activities 
may actually reflect the manifestations of a few factors. While this research has 
also been hampered by the limited quantities of lymphokines available, hybri- 
doma and recombinant DNA technologies have begun to help overcome these 
limitations. 
Macrophage activation has been intensively investigated because it is generally 
agreed that activated macrophages play an essential role in the defense against 
microorganisms and in the immune response against neoplasia (1). Macrophage 
activation mediated by macrophage activation factor (MAF) 1 and gamma inter- 
feron (IFN-'y)  has been characterized by similar morphologic, metabolic, and 
functional changes (2-6) including stimulation of nonspecific tumoricidal activi- 
ties (5), induction of Ia antigen expression (7, 8), increased Fc receptor expression 
(0,  10), production of plasminogen activator (I 1), and production of hydrogen 
peroxide (12). Several investigators (5, 8, 12, 13) have postulated therefore that 
IFN-q~ and MAF may be identical. In support, Schreiber et al. (14) have recently 
demonstrated biosynthetic and biochemical similarities of IFN-'y and MAF pro- 
duced by a  murine T  cell hybridoma (24/G1).  Both the antiviral and  MAF 
activities of 24/G1  cultured supernatants were neutralized by anti-IFN-% but 
not anti-IFN-a and antMFN-B (15).  Although previous investigations (15-17) 
have demonstrated neutralization of MAF activity with polyclonal antMFN-7, 
definitive results could not be ascertained since these antisera were prepared 
from partially purified preparations and could contain antibodies that neutralize 
other lymphokine activities. 
In the present report,  murine IFN-~ produced by recombinant DNA tech- 
niques (18) (>00% pure) was tested for MAF activity; special attention was given 
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tO preclude the presence of endotoxin, which is known to activate macrophages 
(19,  20).  In addition,  rabbit antimurine  IFN-3, was tested for neutralization of 
MAF activity from a variety of sources, including several cloned murine cytotoxic 
T  lymphocyte lines. The results demonstrate that murine IFN-~, is able to activate 
tumoricidal activity in macrophages, and that MAF activity detected in culture 
supernatants which fail to demonstrate IFN-like antiviral activity can be never- 
theless neutralized by antirecombinant murine IFN-3, antibody. 
Materials and Methods 
Animals.  8-12-wk-old male  C57BL/6  mice and outbred Hartley guinea pigs were 
obtained from Charles  River Breeding  Laboratories, Wilmington,  MA.  New  Zealand 
White female rabbits (2 kg, 6 mo old) were obtained from Elkhorn Rabbitry, San Jose, 
CA. 
Cell Lines.  The B16Fw melanoma cell line, derived from a spontaneous melanoma of 
C57BL/6 mouse (21, 22), and the murine T  cell hybridoma clone 3-57 were obtained 
from  Dr.  I. J.  Fidler,  National  Institutes  of Health.  Murine interleukin  2-dependent 
cytotoxic T  lymphocyte clones CTLL-R8, CTLL-R9, CTLL-R11, CTLL-R12 (originally 
obtained from the spleens of CB6F~ mice immunized with leukemia RL-dl) and EL4-17- 
2  (a  subclone of a  benzopyrene-induced murine EL4 thymoma) have been previously 
described  (23,  24).  RPMI  1788  (human  B  lymphoblastoid  cell  line),  WISH  (human 
amnion),  A549  (human  lung  carcinoma)  MDBK  (bovine kidney), and  murine  L-929 
(normal fibroblast) cells were obtained from American Type Culture Collection, Rockville, 
MD. The Lb strain of L-929 cells was obtained from Dr. D. Burke, University of Warwick, 
Coventry, United Kingdom. 
IFN Preparations and IFN Assays.  Murine IFN-a (sp act, 1.7 X 105 U/mg; lot 83002), 
murine IFN-/3 (sp act, 5.3 X 107 U/mg; lot 83005), rabbit IFN (sp act, 4.4 x  105 U/rag; 
lot 81004), and rat IFN (sp act, 3.8  x  106 U/mg; lot 82036) were obtained from Lee 
BioMolecular Co., San Diego, CA. Natural human IFN-3, (sp act, 2 X 105 U/mg), derived 
from phytohemagglutinin- and 4-phorbol-12-myristate-13-acetate (PMA)-stimulated pe- 
ripheral blood mononuclear cells, was obtained from Dr. J. Vilcek, New York University, 
New York. 
Recombinant murine IFN-~, was obtained from gene expression in the CHO (Chinese 
hamster ovary) cell line and in Escherichia  coli as described (18). Murine IFN-3, (sp act, 4 
x  106 U/mg) expressed in E. coli was used in these studies unless otherwise noted. It was 
purified to  homogeneity as determined  by high  pressure  liquid  chromatography and 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and has an amino acid analysis 
indistinguishable from the natural material. A stock solution of I  x  10  ° U/ml contained 
<0.1 ng/ml endotoxin as determined by the Limulus amebocyte lysate (LAL) test (25). 
Recombinant human IFN-a (sp act, 2 x  108 U/mg), recombinant human IFN-a ADbgl 
(sp act, 4.5 X 107 U/rag), recombinant human IFN-/3 (1 x  l0  s U/mg), and recombinant 
human  IFN-3,  (sp act,  2  x  106 U/rag) were also tested for MAF activity. All of these 
materials were >95% estimated purity (as determined by methods described above). 
IFN titers were determined by the inhibition of cytopathic effect in microtiter assays 
(26).  The human  IFN-/3 assay used encephalomyocarditis virus (EMC)  and A549 cells. 
The human  IFN-a assay  was  performed with vesicular stomatitis virus (VSV,  Indiana 
strain) and MDBK cells. The human IFN-3, assay used VSV and WISH cells. Murine IFN 
was assayed with EMC and mouse Lb cells. 
Lymphotoxin Assay.  A semiautomated method to detect lymphotoxin activity, similar to 
that  reported  (27),  was  used.  Cytotoxicity of murine  L-929  cells  was  calculated  by 
measuring  crystal  violet dye  uptake  with  a  Dynatech  MR580  Microelisa autoreader 
(Dynatech Laboratories, Inc., Alexandria, VA). A unit of lymphotoxin activity is defined 
as the reciprocal of the lymphotoxin dilution killing 50% of the target cells (1  x  104 L- 
929 cells). In each assay an internal lymphotoxin standard was included. Human lympho- 
toxin used in these studies was derived from RPMI 1788 and had a specific activity of 1.5 
×  107 U/mg (B. Aggarwal, unpublished results). 814  SVEDERSKY ET AL. 
Rabbit  Antimurine IFN-y.  The material  used to immunize rabbits was  recombinant 
murine IFN-7, expressed in E. coli (18), of the same purity as previously described. The 
immunization schedule was as follows:  On day 0,  200 #g protein (0.5 ml in complete 
Freund's adjuvant) was administered subcutaneously in six different sites. On day 10, 200 
#g protein (in incomplete Freund's adjuvant) was administered intramuscularly. On day 
20, 200 #g protein was administered intravenously. On day 24, the rabbit was bled. 
Affinity Purification of Rabbit Antimurine IFN-~,.  12 mg of highly purified murine IFN- 
~,  was  coupled to  ~2  ml  affi-gel  10  resin  (Bio°Rad  Laboratories,  Richmond,  CA)  as 
previously described (28). Coupling efficiency was determined to be 81%, based on the 
protein mass recovered after washing of the resin. 2 ml of hyperimmune rabbit antimurine 
IFN-~, antiserum  was  dialyzed vs.  phosphate-buffered saline (PBS),  pH  7.4,  and  then 
applied to the murine IFN-~,/affi-gel 10 resin, which had previously been equilibrated vs. 
the same buffer in a  1 ×  10 cm econocolumn (Bio-Rad Laboratories). 97% of the total 
protein applied was recovered in  10-bed volumes of PBS; antibodies (3%  total protein) 
specifically bound to the IFN were eluted in 2-bed volumes 0.1  M sodium citrate, pH 3.0. 
Eluate was immediately adjusted to pH 7.8 with one-half volume 1 M Tris, pH 8.5. By 
enzyme-linked immunoabsorbent assay (ELISA) analysis  (29), all of the murine IFN-~,- 
binding capacity of the original hyperimmune antiserum sample was  recovered in the 
specifically eluted pool; no binding activity was seen in the material that did not bind to 
the murine IFN-'~,/affi-gel 10. 
Neutralization  of MAF Activity.  The IFN-7-neutralizing titer of rabbit antirecombinant 
murine IFN-7 serum was 200,000 U/ml. Neutralization of MAF activity was performed 
by the addition of 15 #1 antiserum to 2 ml of MAF-containing samples.  For neutralization 
of human IFN-a ADbgl, murine IFN-a, and IFN-/3, 120 #1 of antiserum was used. After 
incubation at 37°C for 2 h, the samples were placed directly in the MAF and antiviral 
assays. 
Stimulation for MAF Production.  The medium used to stimulate cells for MAF produc- 
tion was  Eagle's minimum essential medium (MEM)  supplemented with  1 mM sodium 
pyruvate, 0.1  mM nonessential amino acids, 2 mM L-glutamine, twofold vitamin solution, 
100 U/ml  penicillin,  100 #g]ml streptomycin (Gibco Laboratories, Grand Island,  NY) 
and 10% heat-inactivated fetal bovine sera (Sterile Systems, Inc., Logan, UT) (CMEM). 
Murine spleen  cells  were first purified by Ficoll°Paque (Pharmacia  Fine Chemicals, 
Piscataway, N  J) gradients. The monocytes were ctfltured in  10 ml of CMEM (5  ×  106/ 
ml) in  15-ml  plastic centrifuge tubes (Corning Glass  Works, Corning, NY).  After 48 h 
incubation at 37 °C in the presence of 5 #g/ml concanavalin A (Con A) (Sigma Chemical 
Co., St. Louis, MO), all supernatants were sterilized by passage through a 0.22 tzM filter 
(Millex-GS;  Millipore Corp., Bedford, MA) and used immediately. Control supernatants 
were  obtained  from  cells  incubated  without  mitogen  but  reconstituted  to  the  initial 
concentration of mitogen in the stimulated cultures after incubation. 
RPMI  1788, EL4-17-2, hybridoma clone 3-57, or the murine cytotoxic T  cell clones 
were seeded with  1.5  ×  t06 cells into 25-cm  2 plastic tissue culture flasks (Corning Glass 
Works). They were cultured as described above except that, in addition to Con A, 10 ng/ 
ml PMA (Sigma Chemical Co.), which is known to enhance IFN-7 production (30), was 
included. 
Human platelet  residues  (American  Red  Cross,  Needham,  MA),  bovine and  ovine 
spleens (Armour and Company, Dixon, CA), and guinea pig spleen cells were purified by 
Ficoll-Paque and stimulated with Con A as described above. 
Labeling of Tumor Cells.  T-75-cm  2 tissue culture flasks (Corning Glass Works) contain- 
ing 2-3 ×  106 B I 6Fa0 tumor cells in the log phase of growth were labeled with 0.20 #Ci/ 
ml media [12~I]iododeoxyuridine  ([125I]IUdR) (sp act, 100 mCi/#M; New England Nuclear, 
Boston, MA) in the presence of 10  -5 M 5-fluorodeoxyuridine (FUdR) (Sigma Chemical 
Co.). The amount of radioactivity after 24 h was usually 4,000 cpm/104 cells. Before use, 
the labeled cells were washed three times. 
We have observed that the presence of the DNA inhibitor FUdR increases the uptake 
of label and increases the sensitivity of the MAF assay (unpublished observations). Previous 
reports have demonstrated that  treatment of tumor cells  with metabolic inhibitors in- SIMILARITIES OF  IFN-~, AND  MACROPHAGE-ACTIVATING FACTOR  815 
creases target cells' sensitivity to cytolysis by mediators such as lymphotoxin (31), tumor 
necrosis factor (32), and cytolysis by natural killer cells (33). 
Macrophage Activation Assay.  The  macrophage  activation  assay  was  similar  to  that 
described by Fidler et ai. (34) with some modifications. Peritoneal exudate cells (PEC) 
were obtained from mice that were injected intraperitoneaily 5 d previously with  1.5 ml 
thioglycollate (Difco Laboratories, Detroit, MI). The PEC were harvested by injection of 
10 ml cold Ca  ++- and Mg++-free Hank's balanced salt solution (HBSS) (Gibco Laborato- 
ries), washed twice, and adjusted to 1 x  106 cells/ml in warm MEM. 200 #1 were distributed 
in  each well  of a  96-well flat-bottomed microtiter plate (Corning  Glass Works).  After 
incubation in a humidified atmosphere (37°C, 5% CO2) for 1 h, the plates were washed 
with warm MEM and aspirated to remove residual nonadherent cells. 200 #1 of the samples 
to be tested for MAF activity were added in replicates of six in the presence of 5 ng/ml 
lipopolysaccharide (LPS). Significant MAF activity in this assay requires 18 h exposure of 
PEC to activating agents. Hence, the PEC monolayers were activated for 24 h and washed 
in warm MEM before use. At this time,  1 X 104 [l~sI]IUdR-B16Fa0 tumor cells in 200 #1 
were distributed  to  each  well  (effector cell/target  cell  ratio,  20:1).  After  24-48  h  of 
macrophage-tumor cell contact,  100 ~1 of the supernatant was collected and counted for 
isotope  release  in  an  automatic  gamma counter  (model  28150;  Micromedic  Systems, 
Huntsville, AL). Each assay contained tumor cells alone to determine background cyto- 
toxicity (usually 0-5%). In addition, all plates contained 5 ~g/ml LPS (Sigma Chemical 
Co.) in CMEM as a positive control. All experiments were repeated at least three times 
and statistics were performed by the Student's t test. Results are presented as the percent 
specific tumor cytotoxicity (+ SEM) which  was determined by: [(total test supernatant 
cpm -  total control supernatant cpm)/(total cpm plated -  total control supernatant cpm)] 
x  100. The SEM of six replicates did not exceed 5%. 
Results 
Length of Exposure Requirement.  To  determine  the  exposure time period re- 
quired for 'conventional MAF' to stimulate PEC to express MAF activity, PEC 
was treated  with  Con  A-conditioned  media for several time periods (Table  I). 
Significant  MAF  activity  was  observed  only  when  Con  A-conditioned  media 
(which contained  300 U/ml  IFN-~') was exposed to PEC for 18 h; MAF activity 
was increased  by exposure  to  PEC  for  24  h.  No  significant  MAF  activity was 
TABLE  I 
Activation of Peritoneal Exudate Cells (PEC): Length of 
Exposure Requirement 
Length of expo- 
sure 
Percent cytotoxicity by treatment with: 
Con A-condi-  Con A control  LPS  tioned media 
h 
4  6  0  14 
8  5  3  13 
18  20  6  39 
24  54  6  55 
Supernatants  derived  from murine spleen cells cultured  for 48 h in the 
presence of 5 ~tg/ml Con A (Con A-conditioned media) or cultured  cell 
supernatants  adjusted to 5 #g/ml Con A at the end of culture  (Con A 
control), and 5/zg/ml LPS were used to treat murine PEC for the time 
period indicated. PEC were then washed and incubated with [Ia*5]IUdR  - 
labeled B16F10 tumor cells for 24 h. Results, determined by the amount 
of label released, represent the mean percent cytotoxicity of six replicates. 816  SVEDERSKY  ET  AL. 
observed by treatment with the Con A-conditioned  media control (which con- 
tained <6 U/ml IFN-3,). As a positive assay control, treatments of 5 ug/ml  LPS 
were used and  demonstrated  similar  exposure requirements  for expression  of 
MAF activity. 
Macrophage Activation by IFN-~.  Greater than 99% pure recombinant murine 
IFN-~,,  expressed  in E.  coli (18),  from 0.1  to  100  U/ml  was used to stimulate 
MAF activity in PEC (Fig.  1).  Significant levels of MAF activity were observed 
after 24 h of PEC-tumor cell contact in the presence of 100 U/ml, 25 U/ml, or 
10 U/ml of IFN-~, (P <  0.05). When low levels of LPS (5 ng/ml) were included, 
significant MAF activity was detected with as little as 1 U/ml IFN-~,. PEC treated 
with only  5  ng/ml  LPS showed  only background  levels of cytotoxicity,  0%  in 
this experiment. The positive controls (PEC treated with 5 t~g/ml LPS) demon- 
strated 23% cytotoxicity. 
Since the IFN-'~ used for investigation was derived from E. coli and since LPS 
is known to stimulate  macrophages,  various concentrations of LPS were tested 
for MAF activity (Fig.  2). Significant levels of MAF activity were detected with 
LPS treatments, but only when concentrations exceeded 400 ng/ml. This agrees 
with previous reports (35,  36),  where  500  ng/ml  LPS was required  to induce 
significant tumor cytotoxicity. 
Kinetics of Macrophage Activation.  A  kinetic study was performed using treat- 
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FIGURE  1.  Macrophage  activation  by recombinant  murine  IFN-3,.  PEC were  activated  by 
exposure to IFN-~ with (dotted bars) or without (hatched bars) the presence of 5 ng/ml LPS 
for  24  h,  washed,  and incubated  with  [II~S]IUdR-labeled  Bl6Fi0  tumor cells for  24  h.  No 
significant  activation  of  PEC  resulted  after  treatment  with  5  ng/ml  LPS  alone.  Results, 
determined by the amount of 1125 label released,  represent  the mean percent cytotoxicity  (_ 
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FIGURE 2.  Dose response of LPS in the MAF assay.  PEC were activated by exposure to the 
indicated concentrations of LPS, washed, and incubated with [II~5]IUdR-labeled B 16F~0 tumor 
cells for 48 h. Results, determined by the amount of label released, represent the mean percent 
cytotoxicity (:I:SEM) of six replicates. 
ments of 25 U/ml and 100 U/ml recombinant murine IFN-~, and 5 #g/ml LPS 
(Fig. 3). Conventional MAF containing supernatants from C57BL/6 spleen cells 
treated with 5 #g/ml Con A  for 48 h  were included with their controls (spleen 
cells cultured without Con A  but reconstituted to the initial concentration of 
Con A). Significant levels of MAF activity were first detected after 24 h of PEC- 
tumor interaction.  PEC treated  with  100  U/ml  IFN-"r displayed  14.9  +  0.9% 
cytotoxicity (P <  0.001) and 5 #g/ml LPS displayed 8.6 +  1.5% cytotoxicity (P 
<  0.010).  Highest levels of MAF activity were observed at 72  h.  PEC treated 
with IFN-3'  at  100  U/ml,  25  U/ml,  5  #g/ml  LPS,  or  the  Con  A-stimulated 
spleen cell  supernatant  all  displayed significant levels of MAF activity.  IFN-3, 
treatments of 100 U/ml displayed the highest percentage of cytotoxicity (60.8 
__. 4.8%).  The Con A-stimulated spleen cell supernatant displayed 28.5 +  1.9% 
cytotoxicity while its control was not significant. The background cytotoxicity of 
PEC treated with media alone was only 4% (not significant). 
Neutralization of  Macrophage Activation.  The IFN-~, titer of the Con A-treated 
spleen cell supernatant tested was 60  U/ml (Fig.  3).  The level of cytotoxicity 
observed for this supernatant was between the levels of cytotoxicity after treat- 
ment of PEC with 25 and 100 U/ml of IFN-% Since the amount of cytotoxicity 
in the Con A-treated spleen cell supernatant could be explained solely by the 
presence of IFN-3,,  neutralization  experiments were performed  to determine 
whether MAF activity could be detected in the absence of IFN-~, antiviral activity. 818 
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FIGURE 3.  Kinetics of macrophage activation. Treatments of 25 U/ml ([3) and  100  U/ml 
(i) recombinant murine IFN-3,, sttpernatants  from 48-h-cultured Con A-treated spleen cells 
(O), and controls (cells incubated without Con A but reconstituted to the initial concentration 
of Con A (O), in the presence of 5 ng/ml LPS were used for PEC activation. Treatments of 5 
/~g/ml LPS (&) were included as positive assay controls. Con A-treated spleen cell supernatants 
contained 60 U/mi IFN-~, and their controls displayed <4 U/ml IFN-% PEC were activated 
for 24  h,  washed, and incubated  with [II~5]IUdR-labeled B16Fi0 cells for the time periods 
displayed. Results, as determined by the amount of label released, represent the mean percent 
cytotoxicity (±SEM) of six replicates. 
Murine spleen cells were incubated with Con A (as described in Materials and 
Methods) to generate MAF-containing supernatants and were used immediately 
upon collection. Supernatants were diluted  1:4 to  1:256  and divided into two 
portions.  One portion  was  treated  with  rabbit  anti-IFN-3'.  After appropriate 
incubation, all samples were tested in the MAF and IFN-3, assay. The results of 
the antiviral assay (not shown) confirmed antiviral activity in the amount of 90 
U/ml IFN-3,  in  the Con A-treated spleen cell supernatant (1:4 dilution).  The 
same supernatant treated with anti-IFN-3' displayed <4  U/ml.  Similarly, each 
dilution of the supernatant tested with the antibody-treated counterpart was in 
agreement, suggesting that the antiviral activity of IFN-3, was neutralized. High 
levels of MAF activity were found with all dilutions of the Con A-treated spleen 
cell supernatants (Fig.  4).  The highest dilution used (1:256),  which represents 
1.4  U/ml  IFN-3,,  gave significant levels of MAF activity (17.3  +  2.4%,  P  < 
0.001).  When Con A-treated spleen cell supernatants  were treated with anti- 
IFN-% no significant MAF activity remained compared with the antibody con- 
trol.  PEC  treated  with  5  #g/ml  LPS  (positive  assay  control)  demonstrated SIMILARITIES OF  IFN-3,  AND  MACROPHAGE-ACTIVATING FACTOR  819 
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FIGURE 4.  Neutralization  of MAF activity with rabbit  antiserum  to recombinant  murine 
IFN-7.  Con  A-treated  spleen  cell supernatants  (hatched  bars)  and  the  same  supernatants 
treated with antirecombinant murine IFN-3, (r'l) were used to activate PEC. Antibody alone 
(I) and 5 #g/ml LPS treatments (dotted bar) were included as controls. Diluted Con A-treated 
spleen cell supernatants (1:4) contained 90 U/ml IFN-'r. PEC were activated for 24 h, washed, 
and incubated with [II~5]IUdR-labeled B16F10 cells for 48 h.  Results, as determined by the 
amount of label released, represent the mean percent cytotoxicity (_SEM) of six replicates. 
significant levels of MAF activity (36.0 ±  4.1%, P  <  0.001).  Antimurine IFN-~, 
had no effect on LPS stimulation of MAF activity. 
The antimurine  IFN-y antibodies used in  these neutralization experiments 
were generated in rabbits immunized with purified recombinant murine IFN-3,. 
A  possibility  that  neutralization  of MAF activity was  due to  the presence of 
antibody specificities against non-IFN-3, molecules was considered. Therefore, 
the polyclonal antibodies were purified by affinity chromatography. Complete 
neutralization of MAF activity found in  Con A-stimulated murine spleen cell 
supernatants was observed when the polyclonal or affinity-purified antirecombi- 
nant murine IFN-y antibodies were used.  No neutralization  of MAF activity 
occurred when the unbound antibodies (flow through from affinity chromatog- 
raphy purification) was used. This indicated that neutralization of MAF activity 
was specific for the antirecombinant murine IFN-7 antibodies. 
Macrophage Activation by Supernatants of Murine T Lymphocyte Lines.  Three of 
four cloned murine interleukin 2-dependent cytotoxic T  lymphocyte lines that 
were tested for  MAF  production are displayed in  Fig.  5.  All three cell  lines 
(CTLL-R9, CTLL-R 11, and CTLL-R 12) produced MAF activity constitutively, 
and MAF activity was increased when the cells were stimulated with Con A and 820  SVEDERSKY  ET  AL. 
P  60 
E 
R  4o 
C 
E 
N  2O 
T 
0 
C 
Y 
T 
0 
T 
0 
X 
I 
C 
I 
T 
Y 
20 
0 
20 
o 
A  B  C  D  ARC  A  B  C 
1:2  1:8  1:52 
SUPERNATANT  DILUTION 
FIGURE 5.  Neutralization of MAF activity produced by cloned T  lymphocyte lines. Super- 
natants from three cloned interleukin 2-dependent murine T lymphocyte lines stimulated with 
Con A and PMA for 48 h (A), stimulated cell supernatants treated with 400 neutralizing units 
of antirecombinant  IFN-7  (B), unstimulated  cell  supernatants  (C), and  unstimulated  cell 
supernatants  treated  with  antirecombinant  IFN-3"  (D)  were  used.  The  IFN-3' activities of 
stimulated cell supernatants  from CTLL-Rg, CTLL-R11, and CTLL-R19 were 80,  10, and 
10 U/ml, respectively. All unstimulated and antibody-treated supernatants contained <4 U/ 
ml IFN-% PEC were activated for 24 h, washed, and incubated with [I]25]IUdR-iabeled BI6F,0 
cells for 48  h.  Results, as determined by the amount of label released, represent the mean 
percent cytotoxicity (+SEM) of six replicates. 
PMA.  Supernatants  from CTLL-R9  displayed the highest level of MAF  (and 
IFN-3,) activity.  CTLL-R8  did not demonstrate  MAF  (or  IFN-'r)  production, 
even after stimulation (data not shown). While all of the cell lines are able  to 
produce IFN-7 (37), no antiviral activity (<4 U/ml) was detected in unstimulated 
cell line supernatants that displayed MAF activity. This suggested that low levels 
of IFN-3,,  below  the  sensitivity of the  antiviral  assay,  were  produced.  When 
supernatants obtained from stimulated or unstimulated cell lines were treated 
with anti-IFN-'r, complete abrogation of MAF activity resulted. 
Discussion 
Many reagents such as LPS (16,20),  muramyl dipeptide (38),  PMA (39), and 
ionophores (39-41) have been found to activate macrophages. The possibility of 
iymphokines participating in macrophage activation was first reported some 13 
years  ago  when  it  was  demonstrated  that  macrophages  obtained  from  mice 
undergoing tumor rejection  had  tumoricidal  capabilities  (42).  Using purified 
recombinant IFN-7 and affinity-purified antibodies, we have demonstrated that 
murine IFN-'r has potent macrophage activation activity in the cytotoxicity assay SIMILARITIES  OF  IFN-~,  AND  MACROPHAGE-ACTIVATING  FACTOR  821 
employed. The possibility that macrophage activation was due to contaminating 
LPS in IFN-3, preparations can be excluded since these preparations contained 
<0.1  ng/ml LPS. Furthermore, the level of LPS required for MAF activity in 
this assay is 1,000-fold greater. 
In support of these findings, recombinant murine IFN-3, obtained from cul- 
tured supernatants of COS-7  monkey kidney cells has recently been shown to 
display MAF activity (16,  43).  Although IFN-3, from the COS-7  cells was not 
purified, the possibility of macrophage activation by contaminating lymphokines 
and LPS can be excluded. 
Nathan  et  al.  (12)  have  recently demonstrated human monocyte activation 
after  treatment  with purified recombinant human  IFN-3,  expressed  in E.  coli 
(Genentech, Inc.). Significant enhancement of hydrogen peroxide secretion and 
induction  of toxoplasmacidal  activity  occurred  in  a  dose-dependent  manner. 
Furthermore, both activities induced by recombinant IFN-3, could be abrogated 
with neutralizing monoclonal antibody to IFN-3,. Thus, IFN-3' appears to activate 
macrophages in both the murine and human systems. 
Our results and those previously reported (44, 45) demonstrate that 1 U/ml 
IFN-3,  is sufficient to render murine macrophages tumoricidal.  Similarly,  low 
levels  of  IFN-3,  (0.1-1  U/ml)  can  significantly  augment  hydrogen  peroxide 
release and induce toxoplasmacidal activity of macrophages (12). The fact that 
the MAF assay appears to be 5-10-fold more sensitive than the standard antiviral 
assay  for  IFN-3,  may  be  of  importance  in  investigations  where  macrophage 
activation is observed with no detection of antiviral activity (46).  Additionally, 
small molecular weight factors reported to induce macrophage activation (47, 
48) may actually be breakdown products of IFN-3,. We have preliminary evidence 
that fragments of IFN-3, can induce macrophage activation and that the domains 
for antiviral activity and MAF activity may be distinct (manuscript in prepara- 
tion). 
Macrophage activation is thought to occur by at least a two signal process (49, 
50). The first signal is thought to prime the macrophage to make it receptive to 
a  second triggering signal,  as a  result of which the  macrophage develops full 
cytotoxic activity. Our data demonstrate that IFN-3, alone is fully able to activate 
macrophages.  However,  we  have  also  presented  evidence  that  IFN-3,/MAF 
activity may be augmented with small amounts of LPS, as has been demonstrated 
previously  (35,  36).  Other,  less  well-defined  substances  can  also  apparently 
activate  or  modulate the activation  of macrophages, including proteases  (51), 
lipoproteins (52), tumor cell products (53), and prostaglandins (54, 55). 
Table  II represents a  summary of preparations  of murine origin tested  for 
MAF activity. All of the materials tested that displayed antiviral activity possessed 
MAF activity.  Further, neutralization experiments performed with rabbit anti- 
recombinant murine IFN-3,  showed complete abrogation  of MAF activity.  In 
addition to recombinant IFN-3,,  murine IFN-a,  and IFN-13 were also found to 
have MAF activity. This agrees with Roberts et al. (44) and Pace et al. (15), who 
have demonstrated that at least 100-fold more murine IFN-0t//3 than IFN-3, was 
required  to  demonstrate  the  same  amount of MAF  activity.  The  MAF  (and 
antiviral) activity of murine IFN-ot and IFN-13 was not neutralized by antimurine 
IFN-3,. 822  SVEDERSKY  ET  AL. 
TABLE  II 
Summary of Murine Factors Tested  for Neutralization of Murine MAF Activity* 
Source 
Nontreated  Anti-IFN-3, treated* 
Murine  Murine  Murine  Murine  MAF  MAF  IFN activity  IFN activity  activity  activity 
U/ml  U/ml 
Natural IFN-a  15  10,000  14  10,000 
Natural IFN-O  17  10,000  18  10,000 
Recombinant IFN-~, 
Expressed in E. coli  40  100  0  < 16 
Expressed in CHO  72  500  0  <16 
Leukocyte supernatants  44  90  6  <30 
Clone EL4-17-2 thymoma superna  3  <30  4  <30 
tant  0  < 16  ND  ND 
Clone 3-57 hybridoma supernatant 
Cloned T  cell line supernatants  7  <4  ND  ND 
CTLL-R8  50  80  0  <4 
CTLL-R9  30  10  0  <4 
CTLL-R11  38  10  0  <4 
CTLL-R 12 
* Results presented are a  summary of several different experiments.  MAF activity is 
expressed as percent specific cytotoxicity. ND, not determined. 
* Supernatants were treated with antimurine recombinant IFN-~, as described in Ma- 
terials and Methods. 
There appears to be a species specificity for expression of MAF activity in the 
murine assay (Table  III).  Recombinant human IFN-a,  IFN-/31 and IFN-3",  and 
stimulated  leukocyte supernatants  obtained  from human,  bovine,  ovine,  and 
guinea pigs did not c~isplay MAF activity towards murine macrophages. One of 
the purified recombinant human hybrid  IFN-a,  IFN-ot ADbgl  (56),  displayed 
significant levels of murine-directed MAF activity.  This hybrid  IFN  has been 
reported  to  be  the  only human  IFN  to  display  antiviral  (57)  and  antitumor 
properties (58) in murine systems. Interestingly, the MAF (and antiviral) activity 
of human IFN-a ADbgl was not affected by anti-IFN-3". 
In conclusion, murine IFN-3"  appears  to have potent macrophage activation 
capabilities. This MAF activity, as well as that induced from a variety of sources, 
is totally neutralized by affinity-purified antibody to recombinant murine IFN- 
3'. Collectively, these data strongly argue for the biological and antigenic similar- 
ity, if not identity, of these iymphokines. However, it is important to note that 
total abrogation of MAF activity by anti-IFN-3" does not exclude the possibility 
that  MAF  other  than  IFN  exist.  Obviously,  any  antibody  molecule  has  the 
capacity to bind to either the molecule containing the determinant(s) to which it 
was raised  or  to a  nonidentical molecule containing either  the  identical  or  a 
similar determinant(s). Thus, the anti-IFN-3" used in these studies might cross- 
react with a non-IFN-3" protein that had MAF activity. Obtaining a monoclonal 
antimurine  IFN-3"  will  by  useful;  however,  further  studies  involving peptide 
mapping and sequencing will be required to prove identity. SIMILARITIES  OF  IFN-7  AND  MACROPHAGE-ACTIVAT1NG FACTOR 
TABLE III 
Summary of Nonmurine Factors Tested  for Murine MAF Activity* 
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Murine  Murine  Source  MAF 
activity  IFN activity 
U/ml 
Human 
Recombinant IFN-a ADbgl (500 U/ml)  30  500  ~ 
Recombinant IFN-a A (25,000 U/ml)  3  <6 
Recombinant IFN-3 (50,000 U/ml)  6  <6 
Recombinant IFN-3,  (50,000 U/ml)  0  <6 
Natural IFN-'r (50,000 U/ml)  0  <6 
Stimulated RPMI 1788 supernatant (1:2)  0  <6 
Stimulated leukocyte supernatant (1:2)  1  <6 
Human lymphotoxin (1,000 U/ml)  0  <6 
Recombinant human growth hormone (100 ~g/ml)  4  <6 
Other 
Rat IFN (500 U/ml)  0  <30 
Rabbit IFN (500 U/ml)  2  <30 
Stimulated leukocyte supernatants (1:2): 
Guinea pig  0  <30 
Ovine  1  <30 
Bovine  0  <30 
* Results presented are a summary of several different experiments. MAF activity 
is expressed as percent specific cytotoxicity. 
* After treatment with anti-murine IFN-7 as described in Materials and Methods, 
human IFN-a ADbgl demonstrated 31% cytotoxicity and 500 U/ml murine 
antiviral activity. 
Summary 
Murine peritoneal exudate cells (PEC) treated with murine recombinant inter- 
feron-'r  (IFN-~)  (>99%  estimated  purity),  or concanavalin  A-stimulated  spleen 
cell supernatants developed tumoricidal properties (macrophage activation factor 
[MAF] activity).  MAF activity was found to occur with treatments  of 10 U/ml 
IFN-3,,  and  at  levels  as  low  as  1  U/ml  IFN-7  if a  second  signal  (5  ng/ml 
endotoxin) was present in the MAF assay. Endotoxin (lipopolysaccharide  [LPS]) 
alone at these levels  failed to induce MAF;  induction of MAF was observed  at 
1,000-fold  greater  levels.  The  ability  of IFN-3,  to  stimulate  murine  PEC  was 
species specific. Various sources of materials that displayed MAF activity, includ- 
ing supernatants from interleukin 2-dependent cloned cytotoxic murine T  lym- 
phocyte  lines that did not display detectable antiviral  activity, were neutralized 
by antibody raised and affinity purified against recombinant IFN-3,. Thus, IFN- 
%  although never detectable by antiviral assays, appears to be present in many 
lymphokine preparations and has potent macrophage activation capability. 
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